Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China
Author
Abstract
Suggested Citation
DOI: 10.1371/journal.pone.0195117
Download full text from publisher
References listed on IDEAS
- Phil McEwan & Ray Kim & Yong Yuan, 2013. "Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 53-63, February.
- Guo-Feng Chen & Lai Wei & Jing Chen & Zhong-Ping Duan & Xiao-Guang Dou & Qing Xie & Wen-Hong Zhang & Lun-Gen Lu & Jian-Gao Fan & Jun Cheng & Gui-Qiang Wang & Hong Ren & Jiu-Ping Wang & Xing-Xiang Yang, 2016. "Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data," PLOS ONE, Public Library of Science, vol. 11(6), pages 1-13, June.
- Hai Chen & Lijun Chen, 2017. "Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-15, April.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Yin Liu & Xia Zou & Wen Chen & Cheng Gong & Li Ling, 2019. "Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study," IJERPH, MDPI, vol. 16(22), pages 1-15, November.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Alastair Heffernan & Yanling Ma & Shevanthi Nayagam & Polin Chan & Zhongdan Chen & Graham S Cooke & Yan Guo & Chuntao Liu & Mark Thursz & Wanyue Zhang & Xiaobing Zhang & Xiujie Zhang & Manhong Jia & T, 2021. "Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China," PLOS ONE, Public Library of Science, vol. 16(1), pages 1-17, January.
- Constanza L Vargas & Manuel A Espinoza & Andrés Giglio & Alejandro Soza, 2015. "Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile," PLOS ONE, Public Library of Science, vol. 10(11), pages 1-16, November.
- Yin Liu & Hui Zhang & Lei Zhang & Xia Zou & Li Ling, 2020. "Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China," IJERPH, MDPI, vol. 17(3), pages 1-13, January.
- Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
- Hayley Bennett & Jason Gordon & Beverley Jones & Thomas Ward & Samantha Webster & Anupama Kalsekar & Yong Yuan & Michael Brenner & Phil McEwan, 2017. "Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 1001-1011, November.
- Phil McEwan & Thomas Ward & Hayley Bennett & Anupama Kalsekar & Samantha Webster & Michael Brenner & Yong Yuan, 2015. "Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 10(1), pages 1-16, January.
- Pingyu Chen & Min Jin & Yang Cao & Hongchao Li, 2021. "Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 371-387, May.
- Umberto Restelli & Alfredo Alberti & Adriano Lazzarin & Marzia Bonfanti & Carmela Nappi & Davide Croce, 2018. "Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affecte," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 37-44, January.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0195117. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.